BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Olesoxime: Development discontinued

Trophos discontinued development of olesoxime to treat ALS after top-line data from a double-blind, European Phase III trial in 512 patients showed that once-daily 330 mg olesoxime plus riluzole missed the primary endpoint of significantly improving OS at 18 months vs. placebo plus riluzole. Trophos did say a trend in favor of olesoxime was observed on patient function as measured by ALSFRS-R scores...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >